Article Sidebar

PDF
Date Published: 24/10/2021
Abstract Views: 162
Views PDF: 146
DOI: https://doi.org/10.51298/vmj.v506i2.1255
Issue
Vol. 506 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Ngà, Đinh ., Doãn Kỳ, T. ., Anh Tuấn, N. ., Đình Châu, N. ., Quang Biểu, B. ., Thanh Bình, M. ., Trường Giang, Đinh ., Văn Thái, N. ., & Tiến Thịnh, N. . (2021). EFFICACY AND SAFETY OF STEREOTACTIC BODY RADIOTHERAPYFOR TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN THROMBOSIS. Vietnam Medical Journal, 506(2). https://doi.org/10.51298/vmj.v506i2.1255

EFFICACY AND SAFETY OF STEREOTACTIC BODY RADIOTHERAPYFOR TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN THROMBOSIS

Đinh Thị Ngà1, Thái Doãn Kỳ1,, Nguyễn Anh Tuấn1, Nguyễn Đình Châu1, Bùi Quang Biểu1, Mai Thanh Bình1, Đinh Trường Giang1, Nguyễn Văn Thái1, Nguyễn Tiến Thịnh1
1 108 Military Central Hospital

Main Article Content

Abstract

Objective: To evaluate the initial results and toxicity of stereotactic body radiotherapy (SBRT)for treatment ofHepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT). Methods: A prospective study on 31 HCC patients with main branch or trunk portal vein thrombosis were treated by SBRT; follow-up between July, 2018 to June, 2021at Military Central Hospital 108. Ojective Response Rate (ORR), Overall Survival (OS) andtoxicitywere evaluated andanalyzed. Results: The objective response rate after 3 months and 6 months were 67.7% and37.9%, respectively.The median Overall Survival was 13 months. The overall survival rate after 6 months, 1- year was 93.5% and 54.8%. Most of  toxicities were grade 1or2 including thrombocytopenia, liver enzyme elevation, abdominal pain. There was no case of treatment-related death. Conclusion: SBRT is a safe and effective treatment option for advancedHCC with PVT

Article Details

Keywords

Stereotactic body radiotherapy, Hepatocellular Carcinoma, Portal vein thrombosis

References

1. Sung H., Ferlay J., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209-249.
2. Yuta Shibamoto, Akifumi Miyakawa, et al. (2015). Radiobiology of SBRT: 11-25.
3. U.S. Deparment of heath anh human services (2017), Common Terminology Criteria for Adverse Event ( CTCAE) version 5.0: U.S.
4. Eisenhauer E.A, Therasse P., J. Bogaerts, et al.(2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2): 228-47
5. Bustamante J., Llovet JM, et al.(1999). Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic traials Hepatology, 29(62): 7
6. Choi H.S., Kang K. M., et al. (2021). Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol, 17(3): 209-215.
7. Shui Y., W. Yu, et al.(2018). Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol, 13(1): 188
8. Li Zhang, Mian Xi, et al. (2013). Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLoS One, 8(5): e63864
9. Li X., Ye Z., et al.(2021). Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer, 21(1): 701